SKYRIZI
Google image searchProduct monograph
Active ingredient
risankizumab, 60 MG/ML
DIN: 02532107
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE USE VIAL
Schedule: Prescription / Schedule D
Company: ABBVIE CORPORATION
Date: 01-DEC-2022
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC18 — RIZANKIZUMAB (ATC/DDD)
